Table 1.
The efficacy of COVID-19 vaccines
Group | The incidence of COVID-19 infection |
Vaccine efficacy (95% CI) |
|
---|---|---|---|
Vaccine group (95% CI) | Placebo group (95% CI) | VE = 100∗(1–RR) % | |
Vaccine type | |||
Inactivated vaccine (n = 5,705 versus 5,440) | 0.0096 (0.0034– 0.0269) | 0.0357 (0.0310– 0.0409) | 73.11% (34.23–89.03) |
Protein subunit (n = 7,500 versus 7,500) | 0.0008 (0.0004– 0.0018) | 0.0075 (0.0058– 0.0097) | 89.33% (81.44–93.10) |
RNA-based vaccine (n = 48,578 versus 48,732) | 0.0006 (0.0004– 0.0008) | 0.0105 (0.0087– 0.0126) | 94.29% (93.65–95.40) |
Viral vector (non-replicating; n = 40,285 versus 30,275) | 0.0037 (0.0013– 0.0102) | 0.0181 (0.0129– 0.0255) | 79.56% (60.00–89.92) |
Gender | |||
Male (n = 36,245 versus 30,071) | 0.0010 (0.0003– 0.0038) | 0.0137 (0.0094- 0.0200) | 92.70% (81.00–96.81) |
Female (n = 29,774 versus 25,955) | 0.0018 (0.0006– 0.0054) | 0.0148 (0.0098– 0.0223) | 87.84% (75.78–93.88) |
Age | |||
16 to 55 years old (n = 47,958 versus 39,139) | 0.0018 (0.0006– 0.0055) | 0.0162 (0.0117– 0.0224) | 88.89% (75.45–94.87) |
Over 55 years old (n = 19,458 versus 18,390) | 0.0013 (0.0005– 0.0038) | 0.0105 (0.0067– 0.0164) | 87.62% (76.83–92.54) |
Race | |||
Black or African American (n = 9,952 versus 9,979) | 0.0005 (0.0000– 0.0138) | 0.0108 (0.0043– 0.0265) | 95.37% (47.92–100.00) |
White (n = 35,650 versus 35,719) | 0.0016 (0.0004– 0.0063) | 0.0157 (0.0104– 0.0234) | 89.81% (73.08–96.15) |